MA
REGN icon

MYDA Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

MYDA Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,000
Closed -$1.64M – 154
2023
Q1 		$1.64M Buy
2,000
+800
+67% +$603K 0.62% 40
2022
Q4 		$866K Sell
1,200
-800
-40% -$590K 0.53% 45
2022
Q3 		$1.38M Buy
+2,000
New +$1.26M 0.65% 48
2022
Q1 		– Sell
-2,400
Closed -$1.52M – 258
2021
Q4 		$1.52M Sell
2,400
-8,300
-78% -$5.1M 0.4% 77
2021
Q3 		$6.47M Buy
10,700
+6,700
+168% +$4.16M 1.81% 8
2021
Q2 		$2.23M Buy
+4,000
New +$2.03M 0.56% 51
2020
Q3 		– Sell
-4,000
Closed -$2.43M – 142
2020
Q2 		$2.5M Sell
4,000
-700
-15% -$397K 1.51% 22
2020
Q1 		$2.29M Buy
+4,700
New +$1.94M 1.43% 19

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MYDA Advisors's REGN Position: Q2 2023 in Review

MYDA Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 2,000 shares — an estimated $1.64M sold.

MYDA Advisors first reported a position in REGN in Q1 2020 and held it in 8 quarters. The position peaked at $6.47M in Q3 2021. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • MYDA Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • MYDA Advisors sold 2,000 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $1.64M.
  • MYDA Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 8 quarters.
  • MYDA Advisors's Regeneron Pharmaceuticals position peaked at $6.47M in Q3 2021.
  • 1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on MYDA Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.